Diagnosis and management of non-IgE-mediated cow’s milk allergy in infancy: a UK primary care practical guide by Venter, Carina et al.
Venter et al. Clinical and Translational Allergy 2013, 3:23
http://www.ctajournal.com/content/3/1/23REVIEW Open AccessDiagnosis and management of non-IgE-mediated
cow’s milk allergy in infancy - a UK primary care
practical guide
Carina Venter1,2*, Trevor Brown3, Neil Shah4,5, Joanne Walsh6 and Adam T Fox7,8Abstract
The UK NICE guideline on the Diagnosis and Assessment of Food Allergy in Children and Young People was
published in 2011, highlighting the important role of primary care physicians, dietitians, nurses and other
community based health care professionals in the diagnosis and assessment of IgE and non-IgE-mediated food
allergies in children. The guideline suggests that those with suspected IgE-mediated disease and those suspected
to suffer from severe non-IgE-mediated disease are referred on to secondary or tertiary level care. What is evident
from this guideline is that the responsibility for the diagnostic food challenge, ongoing management and
determining of tolerance to cow’s milk in children with less severe non-IgE-mediated food allergies is ultimately
that of the primary care/community based health care staff, but this discussion fell outside of the current NICE
guideline. Some clinical members of the guideline development group (CV, JW, ATF, TB) therefore felt that there
was a particular need to extend this into a more practical guideline for cow’s milk allergy. This subset of the
guideline development group with the additional expertise of a paediatric gastroenterologist (NS) therefore aimed
to produce a UK Primary Care Guideline for the initial clinical recognition of all forms of cow’s milk allergy and the
ongoing management of those with non-severe non-IgE-mediated cow’s milk allergy in the form of algorithms.
These algorithms will be discussed in this review paper, drawing on guidance primarily from the UK NICE guideline,
but also from the DRACMA guidelines, ESPGHAN guidelines, Australian guidelines and the US NIAID guidelines.
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In 2007 the World Health Organisation (WHO) formally
acknowledged that allergy has become the No. 1 envi-
ronmental epidemic disease facing children of the de-
veloped world [1]. A review paper by the World Allergy
Organization [2] estimated that 1.9% to 4.9% of children
suffer from cow's milk protein allergy (CMA), yet per-
ceived food allergy could be up to 10 times higher than
that confirmed by appropriate tests [3,4].
Infants are exposed to cow’s milk protein via the ma-
ternal diet if breast-fed, via standard infant formula, or
when solids are introduced. It is, therefore, not sur-
prising that cow’s milk is often identified as a possible* Correspondence: Carina.venter@port.ac.uk
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reproduction in any medium, provided the orcause for skin and gut problems, particularly in early in-
fancy [3].
Recent evidence indicates that the diagnosis and ma-
nagement of CMA in UK primary care, has room for
significant improvement. During 2009, 1000 infants di-
agnosed as CMA were randomly selected from the UK
GP Health Improvement Network (THIN) database and
subsequently several papers have been published analys-
ing the clinical management of these infants in primary
care. Significant under diagnosis, delayed diagnosis and
incorrect diagnosis were clearly demonstrated. Also, the
initial choice of replacement formula and the decision to
refer on or not, showed worrying inconsistencies [5].
This work, along with other similar evidence, caused
the UK Department of Health to commission a National
Institute for Health and Clinical Excellence (NICE),
Guideline on Food Allergy with a very specific and tar-
geted scope, clearly described in its full title, ‘DiagnosisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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people in primary care and community settings [6].’ This
guideline [6], produced in 2011, recommends that many
manifestations of food allergy could be managed in pri-
mary care. However, this necessitates primary care phy-
sicians (GPs in the UK), dietitians, nurses and other
community based health care professionals having cor-
rect and up-to-date information on the different clinical
presentations of CMA in order to make an accurate
diagnosis, establish a management plan and ensure on-
ward referral when indicated (Figure 1).
Review
Methodology
The NICE guideline was written to direct the diagnosis
of all food allergies. CMA is however, the most clinically
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initial diagnosis of CMA based on the current
international guidelines.
– Give guidance about the ongoing management of
mild to moderate non-IgE-mediated CMA in
primary care.
A literature search was conducted to ensure that all
major food allergies and cow’s milk allergy guidelines
published in the past five years were included. These in-
cluded the World Allergy Organisation’s Guidelines on
Cow’s Milk Allergy [2], the NIAID Food Allergy Guide-
lines from the US [10], the UK NICE Guideline on Food
Allergy in Children and Young People[6], the ESPGHAN
guidelines on the diagnosis and management of cow’s
milk allergy [7]and the Australian consensus statement
on the diagnosis and management of cow’s milk allergy
[11]. All these papers were informed by extensive sys-
tematic reviews of the literature and the group (CV, TB,
JW, NS, ATF), felt that they were rigorous enough to
build this proposed additional practical guideline on. It
is intended to complement the NICE Food Allergy
Guideline.
Prevalence of CMA
Population based studies report that the prevalence of
Cow’s Milk Allergy (CMA) ranges from 1.9 – 4.9% in
young children [2]. UK data from 2008 indicated 2.3% of
1–3 year olds suffer from CMA, the majority of these
presenting with non-IgE-mediated CMA [3]. A meta-
analysis by Rona et al. [4] reported that Cow’s milk
(CM) is one of the most common foods which is respon-
sible for allergic reactions in European children. In gen-
eral, the prognosis for CMA is good, with up to 80-90%
of children developing tolerance before three years of
age [12]. However, CMA may persist up to school age and
may be associated with the later development of other
allergic diseases such as asthma, rhinoconjunctivitis, and
atopic dermatitis [13], as well as other disease manifesta-
tions such as recurrent abdominal pain [14]. It is also
well-known that perceived prevalence may be much
higher [4,12] than that confirmed by appropriate tests.
Cow’s milk formula or cow’s milk containing foods play an
important role in the nutritional intake of children par-
ticularly in early infancy. Onset after infancy has also been
uncommonly reported [3].
Nomenclature
The first step in making the correct diagnosis and man-
aging infants and children with cow’s milk allergy is to
have a good understanding of the immune mechanisms
involved. According to the European Academy for Al-
lergy and Clinical Immunology (EAACI) and the World
Allergy Organisation (WAO) [15], a hypersensitivityreaction to cow’s milk can be referred to as cow’s milk
allergy if it involves the immune system. Non-allergic
cow’s milk hypersensitivity (lactose intolerance) on the
other hand, does not involve the immune system. Cow’s
milk allergy is further divided into IgE-mediated cow’s
milk allergy and non-IgE-mediated cow’s milk allergy
[7]. There is however clinical overlap between some pre-
sentations of cow’s milk allergy as indicated by the US
food allergy guidelines [10].
The different manifestations of CMA
According to the UK NICE guideline [6], food allergy
can manifest as a number of different clinical presenta-
tions, mainly affecting the skin, gastro-intestinal tract
and respiratory systems.
The NICE guideline [6] emphasises that food allergies
should be particularly considered 1) in infants where
there is a family history of allergic disease (but the ab-
sence of a family history of allergy does not exclude the
possibility of becoming allergic), 2) in infants where
symptoms are persistent and affecting different organ
systems and 3) in infants who have been treated for
moderate to severe atopic eczema, gastro-oesophageal
reflux disease (GORD) or other persisting gastrointes-
tinal symptoms (including ‘colic’, loose stools, consti-
pation), but have not responded to the usual initial
therapeutic interventions.
In Figure 2 of the algorithms, we have divided IgE and
non-IgE-mediated CMA into “mild-moderate presenta-
tions” and “severe presentations” to aid in the diagnostic
process, management of CMA and appropriate onward
referral. Therefore, most importantly, Figure 2 gives a
clear message about which infants can be safely diag-
nosed and managed in UK primary care without any on-
ward referral to secondary or tertiary care.
Diagnosis of Cow’s milk allergy
History taking
Taking an allergy focused history forms the cornerstone
of the diagnosis of food allergies including CMA and the
UK NICE guideline [6] recommends that questions
should be asked regarding:
 Any family history of atopic disease in parents or
siblings.
 Any personal history of early atopic disease.
 The infant's feeding history.
 Presenting symptoms and signs that may be
indicating possible CMA.
 Details of previous management, including any
medication and the perceived response to any
management.
 Was there any attempt to change the diet and what
was the outcome?
Figure 2 Different presentations of cow’s milk allergy in infancy.
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questions that should be asked during an allergy focused
diet history, and will be available later this year.
Following on from these questions is the important
step to attempt to differentiate between possible IgE and
non-IgE -mediated allergies (Figure 2) and which “tests”
to do.IgE-Mediated CMA
For the diagnosis of IgE-mediated CMA, the use of skin
prick tests (SPT) or specific serum IgE tests are re-
commended, but these should only be performed by
those competent to interpret the tests [16]. It is import-
ant to understand that a positive SPT or specific serum
IgE test merely indicates sensitisation and does not con-
firm clinical allergy. However, a positive test coupled
with a clear history of a reaction should usually be suffi-
cient to confirm a diagnosis. Although a diagnostic oral
food challenge (after a short period of cow’s milk avoid-
ance) may not be required in most of these cases, if sucha challenge is conducted, it may need to be performed in
a supervised setting in the majority of cases. Liasion with
or referral to a local paediatric allergy team is recom-
mended (see Figure 3).
Non-IgE -Mediated CMA
There are no validated tests for the diagnosis of non-IgE
CMA, apart from the planned avoidance of cow’s milk
and cow’s milk containing foods, followed by reintroduc-
tion as a home challenge to confirm the diagnosis [17].
Home reintroduction/challenges may not be acceptable
in children with severe forms of non-IgE- mediated
cow’s milk allergy, and these children should be referred
to secondary/tertiary care [6].
The role of dietary interventions in the diagnosis of IgE and
non-IgE-mediated CMA
Maternal avoidance of cow’s milk in the case of breast
fed infants, or choosing an appropriate formula for bot-
tle fed/partially bottle fed infants are crucial steps in the
diagnosis of CMA. Mothers excluding cow's milk from
Figure 3 Diagnosis and management of mild to moderate non-IgE CMA in UK primary care.
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vitamin D [18] (Figure 2).
Choosing the most appropriate formula (Figure 3,
Figure 4; Table 1) for the infant based on the clinical
presentation is debated with clear differences between
countries. This choice is really a clinical decision which
should be based on clinical presentation and the nutri-
tional composition and residual allergenicity of the pro-
posed hypoallergenic formula.
The problem clinicians face is that it may appear there
is a large body of evidence about alternatives to cow’s
milk formulae, but most of the research is of low quality
and there are a relatively small number of studies about
each type of formula. There are very few studies com-
paring the different formulae in RCTs head to head and
the clinical profiles of the patients who improved and
did not improve are often very poorly described. This
puts the physician and dietitian in a very difficult pos-
ition when choosing the most appropriate formula for a
particular clinical presentation. In some cases choosing a
soya or an extensively hydrolysed formula (eHF), whichthe infant may also react to, may lead to a false negative
diagnosis. Alternatively, choosing an amino acid formula
(AAF) when not indicated increases the cost burden of
managing CMA and may affect development of tole-
rance (albeit the data is very preliminary at this time)
[19,20].
Table 1 summarises the current international guide-
lines on the use of hypo-allergenic formulae in the diag-
nosis and management of CMA. It is accepted that the
majority of children with CMA will improve on an
extensively hydrolysed formula. It is therefore not sur-
prising that in general, the guidelines suggest the use
of an AAF, as a first line treatment, only for more se-
vere presentations of CMA such as a history of ana-
phylaxis, Heiner Syndrome, Eosinophilic Eosophagitis
and severe gastro-intestinal and/or skin presentations,
usually in association with faltering growth. They rec-
ommend the use of an eHF for all other clinical
presentations.
Unfortunately, apart from the ESPGHAN guidelines
[21], none of the guidelines [2,6,10,11,22] discuss the use
The Hypoallergenic Formulas
The constituents vary between the different individual Extensively Hydrolysed Formulas (eHFs) available and also
between the different individual Amino Acid Formulas (AAFs) available. This can sometimes influence both an infant’s
clinical tolerance and even their perceived apparent palatability of that formula.
The Hypoallergenic Formulas currently most commonly used in the infant age group in the UK for term infants are:  
Extensively Hydrolysed Formulas - eHFs
Casein-based constituents
Nutramigen LIPIL 1              Birth onwards                      Mead Johnson                   400g tin
Nutramigen LIPIL 2              > 6 months of age               Mead Johnson                   400g tin
Similac Alimentum Birth onwards Abbott Nutrition 400g tin
Whey-based constituents*
Althéra Birth onwards Vitaflo 450g tin
Milupa Aptamil Pepti 1        Birth onwards                      Milupa                               400g or 900g  tin
Milupa Aptamil Pepti 2        > 6 months of age               Milupa                               400g or 900g  tin
* Both the whey based extensively hydrolysed formulas contain lactose
Amino Acid-based Formulas - AAFs
Neocate  LCP                      Birth onwards                       Nutricia  SHS                    400g tin
Nutramigen AA  LIPIL        Birth onwards                       Mead Johnson                  400g tin
These are the formulas currently available in the UK, but the range may be different in each country or expanded.
Figure 4 Formulas available for the treatment of CMA in the UK.
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those with multiple food allergies, and those infants who
do not respond to maternal avoidance of cow’s milk
(and other suspected allergens) despite a good clinical
suspicion that these infants may be reacting to residual
allergens. These cases have been reviewed by Hill et al.
[23], Niggeman et al. [24] and Van den Plas et al. [8]
with data suggesting that these groups may benefit from
an AAF. The systematic review by Hill et al. [23] further
suggested that those infants presenting with symptoms
of CMA whilst exclusively breast fed, who may need a
top-up formula or a replacement of breast milk may also
benefit from an AAF.
The use of soya formula in the diagnosis and ma-
nagement of CMA is also debated, with clear differences
between the Australian consensus panel [11] and the
ESPGHAN[7]/AAP[22,25] guidelines. ESPGHAN and
AAP acknowledge that only about 10-14% of infants
with IgE- mediated CMA will also react to soya, but that
this figure is much higher in infants with non-IgE- medi-
ated CMA (25–60%). The two societies therefore recom-
mend that cow’s-milk-based hypoallergenic formulae
should ideally be chosen rather than soya formula in the
management of CMA. In addition, soya formula con-
tains phytate which may affect nutrient absorption and
isoflavonoids in amounts that make soya milk unsuitable
for use in all infants under six months of age. Soya can
however be used in infants older than 6 months if eHF
is not accepted or tolerated, if these hypoallergenic for-
mulae are too expensive, or if there are strong parental
preferences (e.g. vegan diet).In addition, there have been some questions raised re-
garding the use of hypoallergenic formulae containing
lactose in the diagnosis and management of infants and
young children with CMA. ESPGHAN [7] advises that
adverse reactions to lactose in children with CMA is not
reported in the literature and complete avoidance of lac-
tose is not needed in the majority of cases, apart from
those children who have an enteropathy with severe
diarrhoea where there is a secondary lactose intolerance.
Two randomised trials suggested that rice based hydro-
lysed formula is well tolerated by infants with CMA
[26,27] although there are some concerns about the ef-
fect of these formulae on weight gain [28].
Therefore, to summarise the above discussion, taking
into account the lack of good quality studies in this field:
– Breast-feeding is always the preferred way to feed
any infant. In any case where there is a need to
exclude cow’s milk from the maternal diet and a
top-up formula is needed, we suggest in agreement
with Hill et al. [23] an amino acid based formula as
the B-lactoglobulin levels and peptide sizes of cow’s
milk protein in breast milk and those of eHF are
similar to the ranges of B-lactoglobulin seen in
breast milk [29-33].
– AAF is recommended as a first line of treatment for
those infants with a history of anaphylaxis to cow’s
milk, Heiner Syndrome, Eosinophilic Eosophagitis
and severe gastro-intestinal and/or skin
presentations, particularly in association with
faltering growth.
Table 1 Guidance on formula choice
Clinical presentation DRACMA
1st Choice
(Fiocchi et al [2])
ESPGHAN
1st Choice
(Koletzko et al [7])
USA
1st Choice
(Boyce et al [10],
Bahtia et al [22]
American Academy of
Pediatrics [25])
AUSTRALIAN Consensus
Panel 1st Choice
(Allen et al [11])
Anaphylaxis AAF AAF No recommendation AAF
Acute urticaria or angioedema eHF No specific mention but eHF in
general as 1st line treatment for
CMA apart from specific
indications for AAF
No recommendation eHF if < 6 months
Soya if > 6 months
Atopic eczema/dermatitis eHF No specific mention but eHF in
general as 1st line treatment
No recommendation eHF if < 6 months
Soya if > 6 months
eHF if >6 months if also
presenting with faltering
growth
Immediate gastrointestinal
allergy
eHF No specific mention but eHF in
general as 1st line treatment
No recommendation eHF if < 6 months
Soya if > 6 months
eHF if >6 months if also
presenting with faltering
growth
Allergic eosinophilic
oesophagitis
AAF AAF (as well as other eosinophilic
disorders of the gut)
AAF/hypoallergenic formula
(NIAID)
AAF
Gastroesophageal reflux
disease (GORD)
eHF No specific mention but eHF in
general as 1st line treatment
No recommendation eHF if < 6 months
Soya if > 6 months
eHF if >6 months if also
presenting with faltering
growth
Cow’s milk protein-induced
enteropathy
eHF (Severe enteropathy complicated
by faltering growth and
hypoprotenemia) AAF
eHF/AAF eHF if < 6 months
Soya if > 6 months
eHF if >6 if also presenting
with faltering growth
Food protein-induced
enterocolitis syndrome
(FPIES)
eHF AAF Hypoallergenic formula
(NIAID) eHF/AAF
eHF
CM protein-induced
gastroenteritis and
proctocolitis
eHF No specific mention but eHF in
general as 1st line treatment
Gastro-enteritis:
eHF if < 6 months
Soya if > 6 months
eHF if >6 months if also
presenting with faltering
growth
Proctitis: eHF
Severe irritability (colic) eHF No specific mention but eHF in
general as 1st line treatment
Hypoallergenic formula eHF if < 6 months
Soya if > 6 months
eHF if >6 months if also
presenting with faltering
growth
Constipation/Diarrhoea eHF No specific mention but eHF in
general as 1st line treatment
No recommendation eHF if < 6 months
Soya if > 6 months
eHF if >6 months if also
presenting with faltering
growth
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Table 1 Guidance on formula choice (Continued)
Milk-induced chronic
pulmonary disease
(Heiner’s syndrome)
AAF No recommendation No recommendation No recommendation
Faltering growth No recommendation AAF (particularly presenting
with enterocolitis complicated
by hypoprotenemia and
anaemia)
No recommendation See with other conditions –
but defaults to eHF
Breast fed infants – not
responding on maternal
milk avoidance
No recommendation AAF “alternative formulas”
eHF/AAF
No recommendation
Multiple food allergies No recommendation eHF/AAF No recommendation No recommendation
Severe atopic eczema/
dermatitis
No recommendation AAF (particularly if presenting
with faltering growth
complicated by hypoprotenemia
and anaemia)
No recommendation No recommendation
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infants with mild to moderate presentations of CMA
e.g. colic, reflux, diarrhoea, vomiting, eczema in the
absence of faltering growth. eHF containing whey may
not be suitable as a first line of treatment of those
infants with possible secondary lactose intolerance [7].
– Soya formula can be used in infants over 6 months
of age who do not tolerate the eHF, particularly if
they are suffering from IgE mediated CMA in the
absence of sensitisation to soya.
For the purpose of this paper and management of non-
IgE-mediated CMA in UK primary care, Figures 2 and 3
focus on the appropriate choice of hypoallergenic formula
to diagnose and manage non-IgE-mediated CMA and an
additional three files (Additional file 1: Milk Ladder and
Additional file 2: Additional information on milk ladder
and Additional file 3: Milk Ladder Recipes) have been
uploaded on the cows’ milk challenge and reintroduc-
tion procedures to confirm the diagnosis.
The role of the dietitian in the diagnosis and management
of cow’s milk allergy
The UK NICE guideline [6] highlighted the important
role of the dietitian in the diagnosis and management of
CMA in terms of assisting with taking the allergy fo-
cused diet history, choice of formula, monitoring nu-
tritional status, suggesting nutritional supplements and
dietary advice for the breast feeding mother and infant.
The particular role of the dietitian in also providing
appropriate weaning advice cannot be underestimated.
Dietitians can give invaluable advice regarding the level
of cow’s milk allergen avoidance that is required i.e.
which foods should be omitted and which foods can be
tolerated. The role of the dietitian is also to provide
written information on suitable substitute foods, recipes,
online information, label reading and life-style adjust-ments [34-36]. Finally, the dietitian plays a central role
in organising/designing food challenges to diagnose
CMA and determine development op tolerance [34].
Determining development of tolerance to cow’s milk
There is no ideal time for testing for development of tol-
erance, but it is generally accepted that infants with a
proven cow’s milk allergy diagnosis should remain on a
cow’s milk protein free diet until 9–12 months of age
and for at least 6 months [10] prior to reintroduction of
cow’s milk into their diets.
Hospital challenge or onward referral to secondary/
tertiary care should be considered if either of the follow-
ing is true:
1) there has ever been suspicion of an acute onset of
symptoms following ingestion,
2) current atopic eczema and positive specific serum
IgE for CMP.
See Figure 3.
The NICE UK Food Allergy Guideline states that no
child with IgE-mediated food allergy should have a food
challenge in primary care or community settings. All those
remaining children diagnosed as mild-moderate non-IgE
-mediated CMA are suitable for a home challenge. Guid-
ance on how to perform this challenge/reintroduction is
given in the additional three uploaded files.
For the purpose of this paper we have used the
following terminology:
– Food challenge is the term used for deliberate milk
exposure for the purposes of an initial diagnosis of
CMA (usually after a 2–4 week period of avoidance)
[8] and can be done at home or in hospital,
depending on the circumstances.
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deliberate milk exposure for testing for resolution
of CMA after an extended period of avoidance.
For IgE mediated allergy, this is usually done in
hospital as a baked milk challenge or a standard
milk challenge, but can be done at home in
certain circumstances.
– Food reintroduction is the term used for the gradual
reintroduction of cow’ milk after an extended period
of avoidance. This is usually done at home, in non
IgE mediated allergy, as a “milk ladder”.
Challenges/Reintroduction The home reintroduction
performed in children with non-IgE-mediated cow’s milk
allergy could also be referred to as the Milk Ladder.
The Milk Ladder is based around the knowledge that
Cow’s Milk Proteins (CMPs) include casein protein frac-
tions (αs1-,αs2,β-& κ-caseins) and whey protein fractions
(α-lacto globulin & β-lacto globulin) which contain se-
quential and conformational epitopes. Thermal proces-
sing provokes changes to the proteins’ conformational
structures (mainly whey proteins) and may lead to a
change in allergenicity of CM containing foods. Further-
more, the interaction between food proteins and other
components such as carbohydrates and fats during
heating of a complex food (food matrix effects) may re-
duce the milk protein allergenicity [37-39].
Several studies have observed that children with tran-
sient IgE-mediated CMA produce milk specific IgE anti-
bodies against conformational IgE-binding epitopes that
are destroyed during extensive heating or food process-
ing [38,40]. Clinical trials have reported that almost 75%
of children with IgE-mediated CMA may tolerate baked
milk containing foods like muffins, cakes, breads and
waffles [38]. In addition the inclusion of these foods in
these children’s diets seems to accelerate development of
tolerance to CMA compared to the complete milk exclu-
sion approach [37]. The role of processing the develop-
ment of tolerance in children with non-IgE-mediated
CMA has not been investigated, but it does seem to be a
safe approach to perform food challenge in primary care.
There is really very little evidence for devising milk lad-
ders in terms of the effect of heating and dose on the al-
lergenicity of specific foods, the next best option is
therefore to devise guidelines on the basis of clinical/ex-
pert opinion.
A group of dietitians from the UK Wessex Allergy
Network have worked with industry to devise a milk lad-
der in terms of allergenicity of foods, taking into account
the type of milk used in the recipes (whey powder vs.
milk), the temperature of heating and the time of
heating. Affected individuals and their families should,
however, be advised that the classification of milk-
containing foods from lowest to greatest allergenicity ina ‘milk ladder’ is not perfect, but based on the best avai-
lable information.
The authors suggest that the milk ladder is used in the
following way:
– Most children/infants will start at step one of the
ladder. However, some children/infants might have
consumed some of the foods on the “ladder” already
and would therefore not need to start at step one of
the ladder e.g. a child who is already consuming
baked milk containing muffins (step 3) could start
with the introduction of pancakes (step 4).
– In some cases the dietitian/clinician may prefer to
start the ladder with smaller quantities than
suggested e.g. a crumb of a malted milk biscuit, ¼
malted milk biscuit or ½ malted milk biscuit.
– If the food in a certain “step” of the ladder is
tolerated, the authors advise to continue eating the
food and try the food suggested in the next step.
Each step of the ladder can be conducted over any
length of time (for example one day or one week) as
indicated by the dietitian/physician. The duration of
each step will be based on the characteristics of each
individual case.
– For each “step” in the ladder the milk ladder
development group have provided a commercially
available option and a home-made option. This gives
mothers the option to choose what they would like
to give to their children and to adjust the texture to
the developmental milestones of the child/infant
(e.g. the pasta dishes can be mashed up for younger
children).The ladder can also alternate between
commercial and home-made options e.g. buy the
biscuits but bake the muffins.
– There are different levels of care/support in the UK
and one of the reasons for producing this guidance
is to make the dietary aspects of dealing with CMA
more uniform and provide practical guidance in
areas where there is a lack of dietetic support.
If symptoms recur it is suggested that the challenge is
repeated at 4–6 monthly intervals. If milk is tolerated up
to a certain threshold either by amount or degree of
heating / cooking (which reduces the allergenicity), the
level at which it is tolerated should be continued and
a challenge with larger amounts or less heated/cooked
undertaken again in 4–6 months. It is important to
understand that tolerance to milk containing foods re-
lates only to foods tolerated on the ladder. E.g. if a child
reacts to milk chocolate, then consumption of biscuits,
cakes, pancakes, baked milk dishes and pizza should be
safe and should be eaten regularly in the diet. Foods
such as chocolate, yoghurt, cheese and milk should be
avoided in this particular case [35].
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The initial sets of guidelines were trialed in the Northern
Ireland Region of the UK NHS with feedback. The authors
also involved an MSc student from the University of
Southampton who conducted a qualitative study with pri-
mary and secondary care clinicians (GPs, dietitians and
paediatricians – publication in preparation). The Chair of
the Primary Care Group of the British Society of Allergy
and Clinical Immunology and a European Secondary
Care Clinician were asked to review the algorithms.
The authors have taken on board the comments of
all those involved and adjusted the initial guidelines
to what is shown in this publication.
Conclusion
Cow’s milk allergy can present with a spectrum of acute
or delayed symptoms that can be mild to moderate or
severe in nature. Symptoms may affect the respiratory,
cutaneous and gastrointestinal systems, or a combin-
ation of these systems. Diagnosis and management of
non-IgE-mediated CMA can take place in primary care;
however all infants on a cow’s milk exclusion diet should
ideally be referred to a dietitian, preferably before wea-
ning onto solid food takes place. Referral to secondary
care should be made as per the proposed algorithms,
adapted from the UK NICE Food Allergy guideline.
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